Hormonal
Semaglutide (2.4 mg/week) induces significant weight loss (mean -10.09% body weight) and improves cardiometabolic markers (BMI, waist circumference, blood pressure, CRP, lipids) in obese or overweight non-diabetic adults, with efficacy increasing with dose.
For non-diabetic adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, averaging a 10% reduction in body weight. It also improves blood pressure, inflammation (CRP), and lipid profiles. While gastrointestinal side effects like nausea are common, they are typically transient. The treatment is dose-dependent, with higher doses yielding greater weight loss.
Compared with placebo, semaglutide induced a significant body weight loss (MD: −10.09%; 95% CI: −11.84 to −8.33; p ˂ 0.00001), elicited a larger reduction in body mass index (MD: −3.71 kg/m2; 95% CI: −4.33 to −3.09; p ˂ 0.00001) and waist circumference (MD: −8.28 cm; 95% CI: −9.51 to −7.04; p ˂ 0.00001)... Semaglutide exhibited a positive effect on blood pressure, C-reactive protein, and lipid profiles... The results were stable and reliable with dose-dependence.
Why this rating
Systematic review and meta-analysis of 8 RCTs involving 4,567 patients.
Source
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Xueqin Gao et al. · Frontiers in Pharmacology · 2022
DOI 10.3389/fphar.2022.935823
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →